(JABA) Enters Into First Contract in Sustainable Apparel

LAGUNA NIGUEL, Calif., Sept. 8, 2014  — J.D. Hutt Corporation (“JD Hutt” or the “Company”) (Pink Markets: JABA), today announced that it has entered into a contract in the sustainable apparel industry.

In May 2014, the Company announced that it had hired a new CEO, George Powell, and that its business was changing to the sustainable apparel industry. In less than three months, the Company has signed a new agreement and the apparel is already in production. The items will be delivered to the customer in early September 2014.

“We’re excited to have signed our first contract for JD Hutt,” commented George Powell. “It is with a large company and is a private-label product which will carry their brand name and logo. The customer has indicated that they have plans to move forward with a more substantial sustainable product offering in the near term. The speed with which we have signed this contract indicates the willingness of customers to engage in this new business model of sustainable apparel. Our ability to produce a wide range of sustainable and quality products is an asset to the Company’s new direction. Our customer base will expand and allow us to reach critical mass in production and revenues as we introduce sustainable products into a wide array of companies.”

The Company will be changing its name to Green Star Apparel to reflect the new line of business. The formal change will occur once all filings and approvals are completed.

About J.D. Hutt Corporation

JD Hutt’s new business focus is to enter the sustainable apparel industry in order reduce the carbon footprint and make a systemic change in how apparel is made shipped and sold. It will embrace the change and become the ecopreneurs of the industry.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. JD Hutt undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after the date of this communication except as required by law. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication. All forward-looking statements are qualified in their entirety by this cautionary statement.

(MCIG) Obtains Registered Trademark Approval for mCig® and VitaCig® Brands

BELLEVUE, Wash., Sept. 5, 2014  — mCig, Inc. (OTCQB:MCIG) is pleased to announce that the United States Government Patent & Trademark Office (USPTO) has officially issued the following trademarks to the company:

mCig® – Reg. No. 4591689 issued on August 26, 2014 covering electronic cigarettes, and lithium-ion batteries for electronic cigarettes.

VitaCig® – Reg. No. 4588443 issued on August 19, 2014 covering tobacco-free cigarettes and medical devices.

This marks an important milestone for the company as its intellectual property portfolio now hosts two registered trademarks providing ownership over recognizable brands covering two high-growth industries.

“We are pleased with the USPTO decision to award us the registered trademark designations for VitaCig® and mCig®. It feels great knowing that we created these brands, nurtured them, and are now the proud owners. A registered mark is an extremely valuable asset which entitles its owners to commercial ownership over a trade name. Owning the terms “VitaCig” and “mCig” within the electronic cigarette space is an accomplishment for our team and a long-term asset for shareholders.

“For a young company like ours, this development is equally important from an operations perspective. A registered mark allows us to consider other ways to monetize and grow sales. Prior to the granting of the mark, entering into any licensing deals would have been counter-productive without having ownership of our brands. We can now focus on scaling up with partners that have additional resources and capital. We are working on several of these joint ventures and look forward to updating our shareholders when they materialize,” said Paul Rosenberg.

OTCQB Directory Update – The Company has made arrangements to maintain listing on the OTCQB directory and expects to return to the directory in the coming days. Management is of the opinion that there is no discernible difference between its current status being fully reported to the Securities and Exchange Commission (SEC) or being listed on a privately owned directory of companies. In terms of graduating to a higher exchange, an OTCQB directory listing has no implications on such a move. The only requirements are regulatory (SEC) and qualitative (financials performance). We sincerely apologize to our shareholders regarding any confusion relating to this matter.

About mCig, Inc.

mCig, Inc. (OTCQB:MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”) by the world’s 1.2 billion smokers. The company manufactures and retails the mCig® – the world’s most affordable vaporizer priced at only $10. Designed in the USA – the mCig® provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company manufactures and retails the VitaCig®, a $5 nicotine-free eCig that delivers a water-vapor mixed with vitamins and natural flavors. See more at: http://www.mCig.org/, www.Vapolution.com, and www.VitaCig.org.

The company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.

mCig, Inc. (OTCQB:MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig® one of the leading choices for electronic consumption of plant material. – See more at: http://www.mcig.org/investors/investor-opportunity-subpage/

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

CONTACT: Paul Rosenberg
         CEO
         (425) 462-4219

(PRAN) FDA Orphan Drug Designation for PBT2 for Huntington Disease

MELBOURNE, Australia, Sept. 5, 2014  — Prana Biotechnology (ASX: PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.

Orphan drug designation is granted by the FDA to promote the development of drugs for diseases affecting less than 200,000 people in the United States. Orphan drug designation entitles Prana to seven years of market exclusivity for the use of PBT2 in the treatment of Huntington disease; protocol assistance by the FDA to optimize drug development in the preparation of a dossier that will meet regulatory requirements; and reduced fees associated with applying for market approval.

The company will also be applying for Orphan Drug designation in Europe and other jurisdictions.

Huntington disease is a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and behavioral symptoms. More than 30,000 people in the US have Huntington disease and there are currently no treatments for the cognition or executive function symptoms of the disease.

Prana announced in February 2014 that its lead MPAC (Metal Protein Attenuating Compound) PBT2 had met its primary end point of safety and tolerability, and improved measures of cognitive performance – a secondary endpoint in its Reach2HD Phase 2 clinical trial involving 109 people with Huntington disease.

“The FDA’s decision to grant Orphan Drug designation is a reflection of the high unmet need for neurological drugs that can slow, halt or improve the decline of cognition and allow sufferers to have a better quality of life,” said Prana Chairman and CEO Geoffrey Kempler.

“We are very pleased to have received Orphan Drug designation from the FDA, which is a highly important input to determining the commercialisation pathway for PBT2 for the treatment of Huntington disease, and to bring to market as quickly as possible an improved treatment for people suffering from Huntington disease.”

Prana is preparing its Post Phase 2 Trial dossier for submission to the FDA to commence discussions on the next development steps for PBT2.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer’s disease, Huntington disease and other neurodegenerative and movement disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002.  Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other  risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

(NENE) Provides Update on SolarWindow™ Development Activities

New Energy Technologies Inc. (OTCQB:NENE), developer of see-through SolarWindow™ coatings capable of generating electricity on glass and flexible plastics announced today that the Company is successfully progressing ongoing development of its SolarWindow™ devices and modules.

“We’ve achieved significant research and development milestones, and remain sharply focused on commercializing our first-of-its-kind technology for generating electricity on glass windows,” explained Mr. John A. Conklin, President and CEO of New Energy Technologies, Inc. “We’re especially encouraged by the excellent color and transparency of our electricity-generating glass modules, and power production estimates.”

Recently, the Company’s SolarWindow™ set a new record for generating electricity while remaining see-through. New Energy engineers calculate that SolarWindow™ modules modeled for installation on a 50-story building could conservatively produce at least ten times the electrical energy of conventional rooftop photovoltaic (PV) systems and, in some instances, exceed power performance by as much as 50-fold.

Using the Company’s proprietary power production model, engineers estimate that SolarWindow™ installed on a 50-story building could generate enough electricity to power at least 100 homes while eliminating the equivalent carbon emissions produced by vehicles driving approximately 2,750,000 miles per year.

For example, SolarWindow™ modules modeling estimates for the city of Miami, Florida show SolarWindow™ modules could generate over 1.3 million kWh (kilowatt hours) of energy. Today’s rooftop systems could only generate from 28,000 to 102,000 kWh.

The Company envisions SolarWindow™ technology installations on the vast acres of tinted glass surfaces on commercial buildings, skyscrapers, and tall towers. In contrast, conventional solar power systems are limited to very small square-footage rooftops, which are already crowded with service systems. Unlike conventional solar systems, New Energy’s SolarWindow™ can be applied to all four sides of tall towers, generating electricity using natural and artificial light conditions and even shaded areas.

SolarWindow™ is currently under development for eventual commercial deployment in the estimated 80 million detached homes in America and more than five million commercial buildings. The technology is the subject of 42 patent filings, and researchers are on track to advance SolarWindow™ towards full-scale commercial manufacturability – a near-term goal.

About New Energy Technologies, Inc.

New Energy Technologies, Inc., together with its wholly owned subsidiaries, is a developer of next generation alternative and renewable energy technologies. Among the Company’s technologies under development are:

• MotionPower™ roadway systems for generating electricity by capturing the kinetic energy produced by moving vehicles – a patent-pending technology, the subject of 59 US and International patent applications. An estimated 250 million registered vehicles drive more than six billion miles on America’s roadways every day; and
• SolarWindow™ technologies, which generates electricity on see-through glass and flexible plastics with colored tints popular to skyscraper glass. Unlike conventional systems, SolarWindow™ can be applied to all four sides of tall towers, generating electricity using natural and artificial light conditions and even shaded areas. SolarWindow™ uses organic materials, which are dissolved into liquid, ideal for low-cost high-output manufacturing. New Energy’s SolarWindow™ is the subject of 42 patent applications.

Through established relationships with universities, research institutions, and commercial partners, we strive to identify technologies and business opportunities on the leading edge of renewable energy innovation. Unique to our business model is the use of established research infrastructure owned by the various institutions we deal with, saving us significant capital which would otherwise be required for such costs as land and building acquisition, equipment and capital equipment purchases, and other start-up expenses. As a result, we are able to benefit from leading-edge research while employing significantly less capital than conventional organizations.

For additional information, please call Ms. Briana L. Erickson toll-free at 1-800-213-0689 or visit: www.newenergytechnologiesinc.com.

To receive future press releases via email, please visit: http://www.newenergytechnologiesinc.com/investor_alert.

To view the full HTML text of this release, please visit: http://www.newenergytechnologiesinc.com/NENE20140508.

For media inquiries, please contact Jerry Schranz at jschranz@beckermanpr.com, or visit our Media Relations page for additional contact information: http://www.newenergytechnologiesinc.com/media_relations.

For answers to frequently asked questions, please visit our FAQs page: http://www.newenergytechnologiesinc.com/investors/faqs.

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although New Energy Technologies, Inc. (the “Company” or “New Energy Technologies”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company’s products, technical problems with the Company’s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that New Energy Technologies, Inc. will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

(UBRG) Announces NDR Energy Group Signing New Agreement to Supply Natural Gas

IRVINE, Calif., Sept. 5, 2014 — Universal Bioenergy Inc., (OTCPINK:UBRG), a publicly traded diversified energy company that markets and distributes natural gas, petroleum, coal and electricity, announced that its subsidiary NDR Energy Group signed an agreement to supply natural gas to one of the top five largest electric and gas power companies in America. The agreement is projected to generate tens of millions of dollars in additional revenue for the Company from the sales of natural gas.

Universal Bioenergy posted sales of $58.29 million for the nine months ended March 31, 2014, which was a 41.19% increase over the same period last year.

According to the utility customer, it is one of the nation’s largest producers and transporters of energy, and has a portfolio which includes thousands of megawatts of electric power generation, thousands of miles of natural gas transmission pipelines and thousands of miles of electric transmission lines. The utility serves energy customers in 10 states, and operates one of the largest natural gas storage systems in the nation, with hundreds of billions of cubic feet of storage capacity. The utility customer is traded on the New York Stock Exchange and reported over $13.12 billion in revenues in their 2013 Annual Report.

NDR Energy Group’s President and CEO, Ken Harris stated, “At the beginning of 2014, we set out on a difficult course to substantially increase our customer base. In that we already had contracts with some of the largest utilities in the US, we knew that maintaining and growing a customer base of first-in-class, large utilities would have been challenging. This new contract is with one of the five largest electric utilities in the U.S. Additionally, this new customer will be one of the most powerful energy companies concerning the natural gas trades for years to come. There are many potential future synergies concerning this transaction, including our exploration of natural gas exports. In the last six months, we have entered into contracts with two of the five largest electric utilities in the US. These continue to be exciting times for NDR.”

Universal Bioenergy is a high growth diversified energy company that is experiencing double-digit growth. NDR Energy Group, a subsidiary of Universal Bioenergy, sells natural gas to many of the largest public utilities, electric power producers and local gas distribution companies that serve millions of commercial, industrial and residential customer in the United States. The contract limits NDR Energy from disclosing the customer’s name and certain details of the transaction.

About Universal Bioenergy Inc.

Founded in 2004, Universal Bioenergy Inc., is a publicly traded independent diversified energy company that produces and markets natural gas, petroleum, coal and propane. We market energy resources to the largest public utilities, electric power producers and local gas distribution companies in the U.S., that serve millions of commercial, industrial and residential customers. We are also engaged in the acquisition and development of existing or recently discovered oil and gas fields, leases and surface coal mines. For more information visit www.universalbioenergy.com

For inquiries contact: Media Relations: Solomon Ali at 980-225-5376

Safe Harbor Statement– There are matters discussed in this media information that are forward looking statements within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. Such statements are only forecasts and actual events or results may differ materially from those discussed. For a discussion of important factors which could cause actual results to differ from the forward looking statements, refer to Universal Bioenergy Inc.’s most recent annual report and accounts and other SEC filings. The company undertakes no obligation to update publicly, or revise, forward looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.

(TXTM) New Distro Agreements w/ Prominent NY Auto Dealerships On Distracted Driving Solution

Company’s OBD-II Distracted Driving Product to Be Sold in Bright Bay Lincoln, Bright Bay Mazda of Bay Shore, NY, and Boulevard Auto World in Queens, NY

(VNRX) to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference

CEO to Present Data Analysis of Colorectal Cancer Pilot Study of Approximately 1,000 Subjects

NAMUR, Belgium, Sept. 5, 2014 — VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the Aegis Capital 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at Wynn Hotel in Las Vegas, NV.

Mr. Reynolds will present on Thursday, September 11, 2014 at 9:00 a.m. PT. During his presentation, he will discuss top-line results from analysis of an initial representative 938-subject sample from VolitionRx’s 4,800-subject retrospective colorectal cancer blood diagnostic pilot study at Hvidovre Hospital, Denmark. Mr. Reynolds will also outline VolitionRx’s business milestones and growth strategy.

VolitionRx’s NuQ® tests utilize the Company’s proprietary Nucleosomics® platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer signals within the blood. As part of the Denmark trial, VolitionRx is analyzing samples from approximately 4,800 subjects with colorectal cancer, polyps or adenomas, benign bowel diseases or other malignancies, all of whom have undergone a colonoscopy.  Under the trial design, VolitionRx has full access to all Danish national registries and databases. The trial is designed to evaluate the diagnostic accuracy of the NuQ® test for colorectal cancer.

Details of the presentation are as follows:

Investors attending the Conference who would like to schedule a 1-on-1 meeting with VolitionRx management during the conference may do so by contacting their Aegis Capital Corp. representative, or Lee Roth of The Ruth Group at lroth@theruthgroup.com.

For those unable to attend, a live webcast of Mr. Reynolds’ presentation will be available on the Company’s website at www.volitionrx.com. Following his presentation, this webcast will be archived for 90 days.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx’s website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

Safe Harbor Statement

Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

Media Contacts

Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Email: Charlotte.Reynolds@volitionrx.com

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014

Investor Contacts

Scott Powell, Investor Relations
S.Powell@volitionrx.com
Telephone: +1 (917) 721-9480

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

(EWSI) Restructures Expanded China Operations

Audited Financials and Strict Management to Build the Base for the New Contracts

(GDSM) Colorado Ventures Progresses

WILTON, CT / September 4, 2014 / Gold Coast Mining Corp. (OTC Pink: GDSM), provides update on its Colorado activities.

Gold Coast, a leader in innovative concepts and technologies in the marijuana industry, is excited to announce that the Company has reached a verbal agreement for a new grow opportunity and two other projects located in Routt County, CO.

A written term sheet has been submitted to parties for the acquisition/lease of a 3,600 sq. ft. warehouse that will accommodate a substantial grow operation with the capability to install a loft or second level, further expanding production capabilities. The warehouse has all the required infrastructure including 3 phase power and water and a harvest is planned for January/February timeframe and be perpetual thereafter. The Company is waiting on the final signature and will immediately move to final documentation.

Gold Coast and its Denver based legal counsel are performing due diligence on two other properties, one is a family owned 90 acre parcel of which only 40 acres are currently being used as an outdoor grow facility. Plans call to fully develop the 90 acres and construct several greenhouses to allow for year round cultivation.

The third property is a retail medical marijuana dispensary that has several valuable permits including MIP (Marijuana Infused Products) kitchen and wholesale grow licenses.

CEO Michael Shea commented, “I am pleased with the opportunities and I have no doubt that the Company will close transactions in the very, very short term. These transactions are complex and time consuming, but we have the legal structure that allows Gold Coast to participate. Routt County has been more consistent in its view of the industry versus Chaffee County, which just imposed a moratorium on new grow facilities, causing us to put that project on hold despite getting all parties to agree to the terms and conditions.”

“I fully expect events to start unfolding rapidly beginning next week and will keep shareholders and the investment community updated”, Shea concluded.

The o/s remains unchanged from previously reported.

ABOUT GOLD COAST MINING

Gold Coast Mining Corp. is a holding company with interests in the MJ industry. The Company’s goal is create a vertically integrated company and continue its diversification into other high growth industries. The primary goal is generate cash flow to sustain and grow profitability.

Follow us on Twitter at http://twitter.com/GoldCoastMining

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

Contact Info:

Michael Shea

CEO

Gold Coast Mining Corp.

(203) 210-5614

Michael.shea@gdsmholdings.com

http://www.gdsmholdings.com

http://www.mj-xchange.com

http://www.mj-merchant.com

http://420concept.com

(MBIOF) Enters Into Revenue Sharing Agreement With Producers of “Where’s My Lamborghini”

Liolios Group, Inc.
Scott Liolios
Investor Relations
1-949-574-3860
lxv@liolios.com

(IDVC) Adds New Officer and Director

Salt Lake City, UT / September 4, 2014 / Infrastructure Developments Corporation (OTC: IDVC) announced today that Cyril Means III has accepted a position as a director and as secretary of the company.

“Cyril Means has extensive experience in United States securities law, mergers and acquisitions, and finance,” said IDVC CEO Eric Montandon. “We are actively pursuing acquisitions and his expertise will be critical in our due diligence process and our evaluation and pursuit of new business ventures.”

Mr. Means graduated from New York Law School in 1992 with a Juris Doctorate, and is currently licensed by the New York Bar Association. He served as in house counsel to J.J. Bonamuso & Company, a New York commercial real estate company, from 1993 to 1994, and served as General Counsel, Corporate Counsel, Vice President, and Executive Vice President with the Aegis Consumer Funding Group from 1995 to 1999, overseeing corporate and consumer compliance, negotiating credit facilities in excess of $1 billion, and serving as issuers’ counsel for the company’s asset backed securities program. He served as Vice President and General Counsel to Dollar Financial Group, Inc., from 1999 to 2005, completing numerous domestic and international mergers and acquisitions, negotiating credit facilities, and coordinating federal and state lobbying efforts on matters affecting the company. Mr. Means has been semi-retired since 2005.

Infrastructure Developments Corporation:

IDVC is a publicly listed project management firm headquartered in the United States. IDVC’s mission is to bring world-class execution to the international construction and project management industry, and to expand into selected complementary businesses in high-growth international markets. The company is currently focusing on expanding its recently acquired real estate brokerage firm in Dubai, U.A.E., and is also marketing prefabricated housing in North America, the Middle East, and parts of South-East Asia.

Forward-Looking Statements:

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties including the company’s development, competitive market conditions, and its prospects for securing additional sources of financing as required. The actual results that the company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties. The company encourages the public to read the information provided here in conjunction with its most recent filings on Form 10-Q and Form 10-K. The company’s public filings may be viewed at www.sec.gov.

Contact:

Eric Montandon – CEO
Infrastructure Developments Corp., Inc.
eric@idvc.us
www.idvc.us
+971 50 553 2590

(MSPC) Acquisition of Tulasir Villa Spa and Hotel in Coche Island, Venezuela

MIAMI, FL, United States, via ETELIGIS INC., 09/04/2014 – – Today Metrospaces, Inc. (OTC PINK: MSPC), (PINKSHEETS: MSPC), a real estate investment and development company focused on building & reselling condominiums and Luxury High-End Hotels, principally in urban areas of Latin America, is happy to announce that it has acquired the Coche Island hotel project located in Coche Island, Venezuela.

Metrospaces has recently acquired a 50% stake in this exceptional 28-villa luxury hotel and spa. The company has an option to acquire an additional 10% from current shareholders. This destination hotel will have 28 luxury villas of 680ft2 of space, each unit will have its own Jacuzzi and kitchen made for gourmet dinners specially ordered by our guests. This project will be aimed at the luxury destination segment with forecasted room rates of $300 per night.

This represents an amazing testament to our ability to drive value by finding amazing hotel development opportunities and being able to capitalize on them. We have hit the ground running on this project and are looking to have permits renewed and bank financing approved by 1Q of 2015, Mr. Brito said. This will be our second hotel project in Venezuela in only 9 months. We certainly expect to be able to continue to find exceptional hotel investment and development deals in the region.

VISUAL PRESENTATION DOWNLOAD LINK ON TULASIR VILLA SPA AND HOTEL:

https://db.tt/YYK50THw

VISUAL PRESENTATION ON ORINOCO HOTEL PROJECT LINK:

https://db.tt/pE9Bsfnr

For more information about Coche Island, please see:

http://en.wikipedia.org/wiki/Coche_Island

About Metrospaces:

Metrospaces www.metrospaces.net is a publicly traded real estate investment and development company which acquires land, designs, builds, develops, and then resells condominiums and Luxury High-End Hotels, principally in urban areas of Latin America. The companys current projects are located in Buenos Aires, Argentina, and Caracas, Venezuela.

Six years ago, Metrospaces shareholders saw a unique opportunity to participate in several exciting property markets around the world. Through their world-wide network of highly recognized real estate entrepreneurs, the company was able to capitalize on unique real estate development opportunities. Since Inception, the company has leveraged those relationships along with extensive financial expertise and transformed excellence by results.

Metrospaces is a boutique real estate development company, a product of the alliance of Metrospace shareholders, along with an elite group of real estate professionals and entrepreneurs located around the world. Company shareholders have extensive careers in real estate financing worldwide, and have funded projects both in the Americas and across Europe, valued in excess of US $350Million.

Metrospaces majority shareholders have partnered with Investors on Elite properties, including The London BVLGARI 5 Star Hotel, and is currently involved in negotiations for the development of several elite luxury properties in South America.

Among Metrospaces partners are architects, real estate developers, agents, and attorneys of the highest standing, with extensive experience in the global property market.

Metrospaces was originally founded by company president Oscar Brito.

Relevant Links:

www.metrospaces.net

Safe Harbor Statement:

Statements in this news release may be forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Metrospaces Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

CONTACT:

Metrospaces, Inc.

Tel: 305-600-0407

Investor Relations:

investors@metrospaces.net

(SWRF) Names Susan Sjo as CEO

(CYBK) Acquires 100% Of EPA Petroleum, Inc.

CYBK to Spin off Cyber-Thingy as a dividend to its shareholders

DEBARY, Fla., Sept. 3, 2014  — Cyber Kiosk Solutions, Inc. (OTC PINK: CYBK) is pleased to announce the Company has acquired EPA Petroleum, Inc.(EPA) as a wholly owned subsidiary for 300 million shares of Restricted Common stock and Nathan Hall has been appointed the sole officer and director of CYBK.

EPA Petroleum, Inc. will be the new operating company within CYBK.  The former officers and directors have resigned and Christopher J Clarke is returning 65 million shares of Common stock back to the Company.

EPA Petroleum, Inc. (EPA) is an oil drilling company with operations in Pennsylvania. EPA currently has 4 groups of 10 Oil Well blocks to be able to drill on over 250 acres of land and has oil drilling underway on the same drilling lease.  EPA focuses in on a niche area of drilling that is very conservative focusing in on benefits from the tax deductions available for an oil and gas drilling investment including intangible drilling costs, depreciation, operating costs, and percentage depletion. Structured properly, partners may offset their taxable income gained from other sources with the substantial deductions available from investing in oil and gas wells.

EPA currently targets oil drilling opportunities between 1 to 3000 feet in depth with most oil wells being between 1000 to 1300ft feet. This limits the risk of drilling a dry hole along with many other mitigating factors. EPA chooses its locations based on proven reserves and geology/nuclear well reports in the region. The company does NOT do any “Wild Cat Drilling” and EPA’s areas of drilling are in the vicinity of where Quaker State Oil, Pennzoil, and the Rockefeller families all began in the oil business.

After reviewing geology reports EPA’s oil drilling program expects between 850 to 1500 barrels of oil per well, in year one. Some wells in the area have produced higher yields in year one and oil yields may fluctuate. The company’s current operations are in the Oil City, Pennsylvania and Venango County, Pennsylvania areas that have historical proven reserves and are located within miles of the birth of the Oil Industry (Titusville, Pennsylvania).  Due to hydraulic fracking, these areas have come back alive and are producing oil again.

At the end of June EPA had $300,000 in cash in the bank and has its own investment source, which has committed funds for future land leases and drilling operations. This gives the Company an advantage of not having to sell shares in the market to raise capital for future operations.  The Company headed by Nathan Hall has agreed not to do a reverse split for a minimum of one year, allowing it time to evaluate market conditions.

The Company, simultaneously with the Closing of the EPA transaction, moved all of its contracts, agreements, LOI’s and any other agreement whether written or oral into Cyber-Thingy, Inc., of which Oren Manelis has been appointed as the Sole officer and director of the company.

The Company will file with FINRA to change the name, the symbol and effect a spin off of Cyber-Thingy, Inc., to its shareholders no later then October 10, 2014.  Next week CYBK will announce an official record date and details for the Spin Off of Cyber-Thingy.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

(BOLT) To Be Acquired By (TDY)

THOUSAND OAKS, Calif. and NORWALK, Conn., Sept. 3, 2014 — Teledyne Technologies Incorporated (NYSE:TDY) (“Teledyne”) and Bolt Technology Corporation (Nasdaq:BOLT) (“Bolt”) jointly announced today that they have entered into a definitive agreement that provides for the merger of Bolt with a wholly-owned subsidiary of Teledyne. Pursuant to the transaction, Teledyne will acquire all of the outstanding common shares of Bolt for $22.00 per share payable in cash. The definitive agreement contemplates that Bolt will pay its previously announced quarterly dividend of $0.09 per common share, payable on October 2, 2014, to stockholders of record on September 3, 2014. The aggregate value for the transaction is approximately $171 million, taking into account Bolt’s stock options and net cash as of March 31, 2014. The transaction was unanimously approved by the Boards of Directors of Teledyne and Bolt. In addition, Bolt’s directors and executive officers have agreed to vote their shares in favor of the transaction.

Since 1965, Bolt has been a leading supplier of marine seismic energy sources and replacement parts for offshore energy exploration. Bolt also develops and manufactures high-reliability underwater cables and connectors, as well as related electronic controllers, monitoring systems and other auxiliary equipment. Through its SeaBotix business, Bolt is a leading designer and manufacturer of miniature underwater remotely operated vehicles (Mini ROVs) used in maritime security, search and rescue, aquaculture, and scientific research applications.

“Bolt will broaden our rich portfolio of marine instrumentation with a number of highly complementary products,” said Dr. Robert Mehrabian, Chairman, President and Chief Executive Officer of Teledyne. “Bolt’s geophysical acoustic sources will fit well with our existing hydrophone arrays, which listen for the echoes from these sound sources. Bolt would also bring unique connector technology, products and customers to our subsea interconnect businesses. Finally, SeaBotix expands our marine systems business by adding inspection-class ROVs to our autonomous underwater vehicles (AUVs), while also providing more platforms to use our extensive line of marine sensors.”

Raymond M. Soto, Bolt’s Chairman and Chief Executive Officer, commented, “This transaction rewards our shareholders, while providing exciting opportunities for both our customers and employees. Our respective companies have complementary products and technology, and given Teledyne’s resources, we believe that we can accelerate the development of new products, such as our environmentally friendly marine seismic energy source.”

Johnson Rice & Company L.L.C. is acting as exclusive financial advisor and Levett Rockwood P.C. and Edwards Wildman Palmer LLP are acting as legal counsel to Bolt. McGuireWoods LLP is acting as legal counsel to Teledyne.

About Teledyne Technologies

Teledyne Technologies is a leading provider of sophisticated instrumentation, digital imaging products and software, aerospace and defense electronics, and engineered systems. Teledyne Technologies’ operations are primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne Technologies’ website at www.teledyne.com.

About Bolt Technology Corporation

Bolt Technology Corporation is a leading worldwide developer and manufacturer of marine seismic data acquisition equipment used for offshore oil and natural gas exploration. Bolt, through its SeaBotix Inc. subsidiary, is also a developer and manufacturer of remotely operated robotic vehicles systems used for a variety of underwater tasks.

Additional Information About the Acquisition and Where to Find It

This press release is for informational purposes only. It does not constitute an offer to purchase shares of Bolt Technology Corporation or a solicitation or recommendation statement under the rules and regulations of the SEC. Bolt will publicly file a Form 8-K with the SEC containing the terms of the definitive merger agreement, and plans to mail a proxy statement to stockholders of Bolt in connection with the proposed transaction. Investors and security holders of Bolt are urged to read the proxy statement and other relevant materials when they become available because they will contain important information about Teledyne, Bolt and the proposed transaction. Investors and security holders may obtain a free copy of these materials (when they are available) and other documents filed with the Securities and Exchange Commission at the SEC’s web site at www.sec.gov. A free copy of the proxy statement, when it becomes available, may also be obtained from Bolt Technology Corporation, Four Duke Place, Norwalk, Connecticut 06854, Attn: Investor Relations. In addition, investors and security holders may access copies of the documents filed with the SEC by Bolt on Bolt’s web site at www.bolt-technology.com. Bolt, Teledyne and their executive officers and directors may be deemed to be participants in the solicitation of proxies from its stockholders with respect to the proposed transaction. Information regarding the interests of the officers and directors of Bolt in the proposed transaction will be included in the proxy statement, and information regarding the officers and directors of Teledyne is included in its most recent Annual Report on Form 10-K and its most recent Proxy Statement filed with the SEC. The consummation of the proposed transaction is subject to the approval of Bolt’s stockholders as well as other customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Forward-Looking Information Cautionary Notice

This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, with respect to management’s beliefs about the financial condition, results of operations and businesses of Teledyne and Bolt in the future. Forward-looking information involves risks and uncertainties, is based on the current expectations of the management of Bolt and Teledyne and is subject to uncertainty and changes in circumstances. The forward-looking information contained herein may include statements about the expected effects on Teledyne of the transaction, the anticipated timing and scope of the transaction, expected timing of the completion of the transaction, anticipated earnings enhancements, estimated cost savings and other synergies, costs to be incurred in achieving synergies, anticipated capital expenditures and product developments, other strategic options and all other statements in this announcement other than historical facts. Forward-looking information includes, without limitation, statements typically containing words such as “intends”, “expects”, “anticipates”, “targets”, “estimates” and words of similar import. By its nature, forward-looking information is not a guarantee of future performance or results and involves risks and uncertainties because it relates to events and depends on circumstances that will occur in the future. Actual results could differ materially from this forward-looking information. Many factors could change anticipated results, including Teledyne’s ability to integrate Bolt’s operations, retain customers and key employees and achieve operating synergies, the ability to develop and market new competitive products, risks associated with global economic conditions and fluctuations in offshore energy activity, failure of the requisite number of Bolts stockholders to approve the transaction, operating results of Bolt being lower than anticipated, and unexpected acquisition-related costs and expenses. Certain of these and other factors that could affect Bolt’s business are discussed in Bolt’s Annual Report for the fiscal year ended June 30, 2013 and Bolt’s Quarterly Reports on Form 10-Q for the periods ending September 30, 2013, December 31, 2013 and March 31, 2014. Additional information concerning factors that could cause actual results to differ materially from those projected in the forward-looking statements is contained in Teledyne’s periodic filings with the Securities and Exchange Commission, including its 2013 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Neither Teledyne nor Bolt undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

CONTACT: Jason VanWees
         SVP, Strategy and M&A
         Teledyne Technologies
         (805) 373-4542

         Raymond M. Soto
         Chairman and CEO
         Bolt Technology Corporation
         (203) 853-0700

(CBLI) Announces Green Light Pre-Emergency Use Authorization Application, Entolimod

Conference Call Today at 11:00 AM ET

(INFI) Enters into Master Clinical Supply Agreement with Roche

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has entered into a master clinical supply agreement with Roche under which Roche will supply Gazyva^TM (obinutuzumab) to Infinity for use in planned clinical studies to evaluate the combination of Gazyva and duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers. The companies have also entered into a material transfer agreement under which Infinity is supplying Roche with duvelisib for use in Roche’s preclinical and translational research to evaluate the combination of duvelisib and Gazyva.

“We believe that duvelisib has the potential to be the best-in-class PI3K inhibitor and that Gazyva has the potential to be the best-in-class anti-CD20 therapy, so we are pleased to have entered into these agreements with Roche. Our ability to evaluate duvelisib in combination with Gazyva in multiple clinical studies is part of Infinity’s strategy to combine duvelisib with both current standards of care and novel, targeted therapies,” stated Julian Adams, president of research and development at Infinity. “We look forward to beginning clinical studies of duvelisib plus Gazyva, including the first study in indolent non-Hodgkin lymphoma evaluating Gazyva in combination with a PI3K inhibitor.”

In 2014, Infinity plans to initiate a Phase 1b/2 clinical study of duvelisib in combination with Gazyva or rituximab in patients with previously untreated indolent non-Hodgkin lymphoma (iNHL). Infinity also expects to initiate in 2014 a Phase 1b clinical study of duvelisib in combination with Gazyva in patients with chronic lymphocytic leukemia (CLL) whose disease has progressed following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. These studies are in addition to Infinity’s plans to initiate this year DYNAMO+R^TM, a global Phase 3 study evaluating duvelisib in combination with rituximab in patients with follicular lymphoma. Other global, registration-focused trials evaluating the safety and efficacy of duvelisib are ongoing, including DYNAMO^TM, a Phase 2 study in patients with iNHL, and DUO^TM, a Phase 3 study in patients with CLL.

Roche also plans to study duvelisib as part of its preclinical and translational efforts in hematology. These research efforts will be part of Roche’s ongoing efforts to further understand the therapeutic potential of Gazyva in combination with both approved medicines and experimental therapies.

“Duvelisib targets both PI3K-delta and PI3K-gamma, two proteins that play critical roles in the growth and survival of tumor cells,” stated Vito Palombella, Ph.D., chief scientific officer at Infinity. “We are pleased that Roche’s preclinical and translational science teams will be studying duvelisib in combination with Gazyva to understand how they may work together. We hope Roche’s research will contribute to our understanding of how duvelisib works in combination with other therapies, including Gazyva, as we seek to improve outcomes for patients.”

About the Development of Duvelisib for the Treatment of Blood Cancers

Infinity is developing duvelisib, an oral inhibitor of Class I PI3K-delta,gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity. The PI3K-delta,gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and mostly non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of hematologic malignancies as well as inflammatory diseases.

In 2013, Infinity launched the DUETTS^TM (Duvelisib Trials in Hematologic Malignancies) program, a worldwide investigation of duvelisib in blood cancers. As part of the DUETTS program, patient enrollment is ongoing in DYNAMO^TM, a Phase 2 monotherapy study designed to evaluate the safety and efficacy of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) (ClinicalTrials.gov Identifier NCT01882803), and DUO^TM, a Phase 3 monotherapy study designed to evaluate the safety and efficacy of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) (NCT02004522). DYNAMO+R^TM, a Phase 3 study of duvelisib in combination with rituximab in relapsed follicular lymphoma (NCT02204982), is expected to start in 2014.

Additionally, a Phase 1 study of duvelisib in patients with advanced blood cancers is ongoing (NCT01476657).

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, please refer to the company’s website at www.infi.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the Company’s expectations about: the supply of Gazyva by Roche; the therapeutic potential of duvelisib as a monotherapy and in combination with other therapies such as obinutuzumab; plans to initiate additional clinical trials with duvelisib; and its ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company’s current expectations. For example, there can be no guarantee that Infinity will initiate clinical trials in the time frames it has estimated, that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical development phases, or that development of any of Infinity’s product candidates will continue. Further, there can be no guarantee that Roche will meet its obligations under the master clinical supply agreement, or that any positive developments in Infinity’s product portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Infinity’s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Infinity’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of agents by Infinity’s competitors for diseases in which Infinity is currently developing or intends to develop its product candidates; and Infinity’s ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. These and other risks which may impact management’s expectations are described in greater detail under the caption “Risk Factors” included in Infinity’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 11, 2014, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

(PENC) Announces New Trading Symbol

Stock Continues Trading on the OTCQB

(UBRG) Announces NDR Energy Group Signs New Agreement to Supply Natural Gas

IRVINE, Calif., Sept. 3, 2014  — Universal Bioenergy Inc., (OTCPINK:UBRG), a publicly traded diversified energy company that markets and distributes natural gas, petroleum, coal and electricity, announced that its subsidiary NDR Energy Group signed an agreement to supply natural gas to one of the top five largest electric and gas power companies in America. The agreement is projected to generate tens of millions of dollars in additional revenue for the Company from the sales of natural gas.

Universal Bioenergy posted sales of $58.29 million for the nine months ended March 31, 2014, which was a 41.19% increase over the same period last year.

According to the utility customer, it is one of the nation’s largest producers and transporters of energy, and has a portfolio which includes thousands of megawatts of electric power generation, thousands of miles of natural gas transmission pipelines and thousands of miles of electric transmission lines. The utility serves energy customers in 10 states, and operates one of the largest natural gas storage systems in the nation, with hundreds of billions of cubic feet of storage capacity. The utility customer is traded on the New York Stock Exchange and reported over $13.12 billion in revenues in their 2013 Annual Report.

NDR Energy Group’s President and CEO, Ken Harris stated, “At the beginning of 2014, we set out on a difficult course to substantially increase our customer base. In that we already had contracts with some of the largest utilities in the US, we knew that maintaining and growing a customer base of first-in-class, large utilities would have been challenging. This new contract is with one of the five largest electric utilities in the U.S. Additionally, this new customer will be one of the most powerful energy companies concerning the natural gas trades for years to come. There are many potential future synergies concerning this transaction, including our exploration of natural gas exports. In the last six months, we have entered into contracts with two of the five largest electric utilities in the US. These continue to be exciting times for NDR.”

Universal Bioenergy is a high growth diversified energy company that is experiencing double-digit growth. NDR Energy Group, a subsidiary of Universal Bioenergy, sells natural gas to many of the largest public utilities, electric power producers and local gas distribution companies that serve millions of commercial, industrial and residential customer in the United States. The contract limits NDR Energy from disclosing the customer’s name and certain details of the transaction.

About Universal Bioenergy Inc.

Founded in 2004, Universal Bioenergy Inc., is a publicly traded independent diversified energy company that produces and markets natural gas, petroleum, coal and propane. We market energy resources to the largest public utilities, electric power producers and local gas distribution companies in the U.S., that serve millions of commercial, industrial and residential customers. We are also engaged in the acquisition and development of existing or recently discovered oil and gas fields, leases and surface coal mines. For more information visit www.universalbioenergy.com

For inquiries contact: Media Relations: Solomon Ali at 980-225-5376

Safe Harbor Statement – There are matters discussed in this media information that are forward looking statements within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. Such statements are only forecasts and actual events or results may differ materially from those discussed. For a discussion of important factors which could cause actual results to differ from the forward looking statements, refer to Universal Bioenergy Inc.’s most recent annual report and accounts and other SEC filings. The company undertakes no obligation to update publicly, or revise, forward looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.

(CBMG) Launches Clinical Research Study for Cartilage Defect Stem Cell Therapy

PALO ALTO, Calif., Sept. 2, 2014  — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of a study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for Cartilage Defects (CD) resulting from osteoarthritis (OA) or sports injury. Both arthroscopy and the use of magnetic resonance imaging (MRI) will be deployed to further demonstrate the regenerative efficacy of ReJoin^TM on cartilage defects.

“In light of the promising Knee Osteoarthritis Phase IIa six month follow-up results we decided to explore the efficacy of our proprietary ReJoin^TM therapy on an additional orthopedic indication, Cartilage Defects (CD),” said Dr. William (Wei) Cao, Chief Executive Officer of the Company. “We are thankful for the approval by the ethics committee of Shanghai Ninth People’s Hospital for this exploratory clinical research, and very much look forward to finding the promise of ReJoin^TM therapy on CD. The repair of CD would greatly improve the quality of life for CD patients, allowing for greater mobility, flexibility and less pain.”

About the Study

The clinical study is a single-blind, randomly assigned, controlled clinical research study that will enroll thirty patients with the purpose of evaluating the safety and efficacy of haMPCs combined with lavage, debridement, and/or microfracture under arthroscopy treatment for cartilage defects. In addition, this study shall serve as a supporting study of ReJoin^TM for the treatment of Knee Osteoarthritis (KOA) so as to bring additional clinical data to the protocol of future KOA trials.

The study will be conducted by Shanghai Ninth People’s Hospital, a leading teaching hospital affiliated with Shanghai Jiao Tong University School of Medicine. Professor Wang You, Director of the hospital’s orthopedics department and Vice Chairperson of the Chinese Knee Society, will lead the study as Principal Investigator.

About CD in China

Currently in China KOA patients number over 57 million. The incidence of cartilage defect in routine knee arthroscopies has been reported to be almost 300,000 per year. (Source: Market analysis of Chinese arthroscopy, published on July 21, 2014 and “Advances in Orthopedics” Volume 2012, Article ID 528423) Similar to KOA, CD  is an unmet orthopedic medical need.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com

         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         vivian.chen@grayling.com

(YPPN) FotoYapp Begins Global Platform Rollout

FotoYapp allows users to engage social media on a global scale

Corporate Contact
David Lucatch
Founder and CEO
Yappn Corp.
info@yappn.com

Media Contact
Melissa Kubrin
Fingerprint Communication
melissa@fingerprintcom.net

(IDN) CEO Nelson Ludlow Interviewed on Fox Business News

Dr. Nelson Ludlow, Ph.D., CEO of Intellicheck Mobilisa, Inc. (NYSE MKT:IDN), a global leader in identity solutions and wireless security systems, was interviewed on Fox Business News on September 2 about measures individuals can take to ensure their personal security when dealing with banks.

Speaking with Fox Business News host Maria Bartiromo, Dr. Ludlow noted that recent bank hackings are sophisticated and global in nature, and just as large U.S. banks are taking measures to enhance their cybersecurity, individuals can also take specific steps to enhance their personal security. These steps include noticing any unusual activity on bank statements and reporting it to the bank immediately, and using debit cards—whose PIN numbers provide an extra layer of security—whenever possible.

To view the Fox Business News interview in its entirety, please visit the following link: http://video.foxbusiness.com/v/3763037033001/hacking-411-how-to-beef-up-security/ – sp=show-clips/featured

About Intellicheck Mobilisa

Intellicheck Mobilisa is a leading technology company providing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. Products include the Fugitive Finder system, an advanced ID card access control product currently protecting military bases and secure federal locations; ID Check, a patented technology that instantly reads, analyzes, and verifies encoded data in magnetic stripes and barcodes on government-issued IDs, designed to improve the Customer Experience for the financial, hospitality and retail sectors; barZapp™, an ID-checking mobile app that allows a user’s smartphone to check an ID card. For more information on Intellicheck Mobilisa, please visit www.icmobile.com.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. When used in this press release, words such as “will,” “believe,” “expect,” “anticipate,” “encouraged,” and similar expressions, as they relate to the company or its management, as well as assumptions made by and information currently available to the company’s management identify forward-looking statements. Actual results may differ materially from the information presented here. Additional information concerning forward-looking statements is contained under the heading of risk factors listed from time to time in the company’s filings with the SEC. We do not assume any obligation to update the forward-looking information.

(SAMP) 2013 Annual Shareholder Meeting

DALLAS, Sept. 2, 2014  — South American Properties, Inc. (Pink Sheets:SAMP), is pleased to announce that the 2013 annual shareholder meeting was held on Dec. 31, 2013. At that time, the 3 proposals previously announced, which included adding 2 new members to the Board, adopting new Bylaws and amending the Articles of Incorporation, were voted on at the meeting and passed. Mr. Scott Horne delivered the new Corporate Vision and laid out the business plan for the company’s new business venture. During this Shareholder meeting, SAMP received approval to change its name to LTV Funding Corp. This information is on the website www.southamericanproperties.com/annual-meeting-info.html.

South American Properties had to cancel its investment opportunity in South America, as was previously announced, due to a shareholder’s action. This was also the reason for the delay in this announcement.

The new direction of the company is as an asset based or “hard money” lending company to residential and commercial real estate investors. The members of the Board have been involved as owners and operators of other asset based lending operations for over 15 years each. Their expertise in this arena should enable the growth and shareholder value to increase in the company beginning this year.

Following the shareholders’ meeting, the board met and Mr. Jeff Love resigned as President and Chairman of the Board. Mr. Horne was elected as the company’s new President and Chairman. In the following weeks, a more detailed plan to raise capital and begin operations and marketing to real estate investors will be introduced. Currently, steps are being taken to file the necessary paperwork to change the name of the corporation to the shareholder approved name.

As LTV Funding Corp. launches into its new operations in 2014, we are seeking to raise capital in both the public and private markets. Opportunities exist for investors of all sizes to invest with LTV Funding, generating both an attractive interest rate as well as a convertible note arrangement. For more information regarding these opportunities, please visit our website, www.ltvfunding.com.

About LTV Funding Corp:

South American Properties, Inc., formerly Texas Hills Barbecue, Inc. now known as LTV Funding, Inc., is a Nevada Corp. based in Dallas, Texas, will lend acquisition and rehab money for commercial and real estate properties, and other income generating assets located in Texas. The Company believes significant opportunities exist in this arena, and it plans to leverage its close relationships with its investor contacts in Texas. LTV may also enter into real estate projects in other states in the near future.

Forward-Looking Statements

This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings and disclosures at www.OTCmarkets.com.

CONTACT: Scott Horne
         scott@ltvfunding.com
         LTV Funding Corp, f/k/a South American Properties, Inc.
         1400 Gables Court
         Plano, Tx  75075

         Phone: 214/626-8566
         www.ltvfunding.com
         Email:  scott@ltvfunding.com

(AVOP) Launches Renovated Website

Company Enhances Internet Presence With Updated Information and Modernized Design

(DIGX) Executes Letter of Intent With Cannabeez Media, LLC

(EKSO) to Demonstrate Robotic Exoskeleton Technology

RICHMOND, Calif., Aug. 29, 2014 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that Ekso Bionics will be demonstrating their technology at the Academy of Spinal Cord Injury Professionals 2014 Educational Conference and Expo August 31^st thru September 3^rd at Hyatt Regency at the Arch, St. Louis Missouri. With close to 80 suits being used on over 60 centers internationally, Ekso Bionics is the most widely used robotic exoskeleton rehabilitation device worldwide.

Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user’s clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics’ lead product, Ekso^TM, is a wearable bionic suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.

About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company’s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com

Facebook: www.facebook.com/eksobionics

Twitter: @eksobionics

YouTube: http://www.youtube.com/user/EksoBionics/

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above.  Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over.  Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.  Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including, the Company’s Current Report on Form 8-K/A filed on March 31, 2014 and the Company’s latest Form 10-Q filed on May 13, 2014.  The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:
         Heidi Darling, Marketing Manager
         Phone: 415.302.4777
         hdarling@eksobionics.com

         Investor Contact:
         Lauren Glaser, Vice President
         Phone: 646.378.2972
         lglaser@troutgroup.com

(IRMGF) Responds to Trading Activity

Inspiration Mining Corporation
Randy Miller
Chief Executive Officer
416-865-3368
416-842-9000
www.inspirationmining.com

(UTHR) District Court Decision Received In Remodulin Patent Case

SILVER SPRING, Md., Aug. 29, 2014  — United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. District Court for the District of New Jersey has ruled in its favor in the company’s case against Sandoz, Inc. regarding United Therapeutics’ Remodulin^® product.  In his opinion, Judge Peter Sheridan ruled that U.S. Patent No. 6,765,117 is both valid and enforceable against Sandoz, Inc., and enjoined Sandoz from marketing its generic product until the expiration of that patent in October 2017.  Judge Sheridan also ruled that U.S. Patent No. 7,999,007 expiring in 2029 is valid, but would not be infringed by Sandoz’ generic product.  Sandoz filed an Abbreviated New Drug Application in December 2011 seeking to market a generic version of Remodulin, and challenged patents covering Remodulin as part of that application.  United Therapeutics filed the lawsuit that is the subject of this ruling shortly thereafter.

“We are pleased with the Court’s ruling today confirming the validity and enforceability of the ‘117 patent,” said United Therapeutics’ CEO, Martine Rothblatt. “We have always emphasized our investment in scientific advances and the resulting intellectual property that allows us to bring our products to patients, and this decision is a validation of that emphasis.”

United Therapeutics is analyzing the Court’s opinion and assessing its next steps with respect to the ‘007 patent, which may include an appeal of the ruling to the U.S. Court of Appeals for the Federal Circuit.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, among others, statements regarding United Therapeutics’ patents, including next steps with respect to the ‘007 patent.  These forward-looking statements are subject to certain risks and uncertainties and are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and current reports on Form 8-K, which could cause actual results to differ materially from anticipated results. We are providing this information as of August 29, 2014, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.  [uthr-g]

(TECO) Announces Update and Vision Statement

Chris D. Tesarski, Executive Chairman and CEO, States that “September 1, 2014 Marks the Beginning of a New Chapter in the History TREATY Energy”

NEW ORLEANS, Aug. 29, 2014  — TREATY Energy Corporation (OTCQB: TECO), a growth-oriented energy company in the oil and gas industry, today reported that its Board of Directors is pleased to announce the following update and vision statement to its shareholders and the investment community.

Chris D. Tesarski, Executive Chairman and CEO of TREATY Energy Corporation, stated, “September 1, 2014 marks the beginning of a new chapter in the history of TREATY Energy.”

The corporation has signed a LETTER OF INTENT with a private service company, “PRIVCO” to “liberate the oilfield service” assets of TREATY Energy into “PRIVCO” as part of the process to build an exciting, diverse and growth oriented full service company dedicated to optimizing and enhancing oil and gas operations in “the Americas.”

Of particular interest to TREATY shareholders will be the fact that PRIVCO has an executed JOINT VENTURE AGREEMENT with a downhole tool company whose patented process has been credited with optimizing and enhancing production on several hundred wells in Canada, Mexico and the United States.  This process when paired with TREATY’s oilfield services unit, will not only give PRIVCO the ability to optimize TREATY’s production, but also allows PRIVCO the ability to service other clients.  This business arrangement comes with a built in network of six NATIONAL distributors that have been integral in marketing the tool that will now be important to building an opportunity platform for the TREATY oilfield service assets.

In addition, PRIVCO has acquired 50% of the interest of SANDBOX RESOURCE SOLUTIONS LLC of Abilene, TX.  “SANDBOX” has developed a proprietary process for converting “produced formation water” from oil and gas wells into fresh water suitable for a wide variety of applications including oilfield service, agriculture, and many other uses.  The SANDBOX water management system is being used commercially by a Denver-based energy company to integrate into a constructed wetlands project North of the Yellowstone River in Montana that utilizes the treated formation water from an oil battery to provide fresh water for cattle, wildlife, and oilfield applications.  Water hauling costs on this project have been reduced by approximately $3,000 per day.  Over thirty five to forty water-hauling trucks per week have been reduced to three.

TREATY will incorporate the SANDBOX water processing system into its “Stockton” field operations.  Initial drilling reports indicate the presence of oil but also significant quantities of water.  The decision was made to “go uphole”.  Unfortunately, this decision rendered the well basically unproductive.  TREATY’s technical team believes that if they recomplete the well in the lower water bearing zones they can significantly increase oil production.  The SANDBOX system will allow the company to produce significant volumes of fluid without the cost of drilling an injection well. The recycled water will have significant value in drought stricken West Texas.

In speaking about the PRIVCO opportunity Mr. Chris Tesarski, Chairman & CEO of TREATY, stated “TREATY shareholders will be pleased to note that the integration of the PRIVCO service platform will now allow the “500 Well Louisiana Project”, “Project X” (certain contract opportunities in Central America and the Caribbean), and reinvigorated GEOTECHNICALLY DEFINED operations in Belize to move forward, thereby restoring the opportunity for TREATY shareholders to see value derived from what was a previously difficult chapter in the history of the company.  The combination of new management and technically qualified industry personnel in TREATY and PRIVCO will allow value to be realized that had for the most part been written down by the markets and shareholders alike.”

“PRIVCO’s commitment to integrating a full service operation into TREATY’s growth oriented production platform and the ability to network its services to a growing number of energy companies in the Americas make this transaction a very attractive one for TREATY’s shareholders,” says Mr. Tesarski

PRIVCO is currently involved in the process of converting to a publicly traded company by completing the process of acquiring an existing public entity.  Once again, the Board is convinced that this will provide significant additional value to TREATY’s shareholders.  PRIVCO and TREATY will keep shareholders apprised of developments as they occur.

As part of the changes in structure to the company the Board of Directors has negotiated a stock based dividend for all TREATY shareholders in PRIVCO.  During a rollout period of the next 90 days, TREATY shareholders as of September 30, 2014 (or such date as the market regulators might determine), will receive shares of the common stock of PRIVCO at a rate to be determined subject to all regulatory approvals as are common to such transactions.

In keeping with the aforementioned transaction and the commitment of the Board of Directors to increasing shareholder value, the company will undergo a process of defining TREATY’s identity as an ENERGY PRODUCER.  Rooted in a firm belief that the “Americas” hold vast untapped, bypassed and forgotten energy reserves the company intends to continue its focus on “finding new oil and gas in old places.”

“We believe that this is the right place for us to be and welcome other players who focus on exploratory, wildcat plays, but TREATY will continue to focus on what we KNOW got left behind instead of risking shareholder value on what we believe MIGHT be there,” says Mr. Tesarski.

To this end, the company wishes to announce the signing of three (3) new leases (defined by 3D seismic) in the Tuscola, TX area, not far from its Stockton operations.  These leases will give the company the ability to integrate PRIVCO’s service platform into operations thereby giving TREATY a strategic advantage in developing its production operations.  In addition to the 3D seismic, TREATY has access through PRIVCO to thorough geotechnical data to assist in making strong, technically sound strategic development and optimization decisions with regard to its operational platform.

“TREATY shareholders have stuck with the company through some very difficult times.  Liberating the oilfield service assets of TREATY and partnering with PRIVCO will lead to strong growth for our shareholders in two dynamic companies.  A reenergized, reorganized and vibrant energy company and a new, visionary, and technology savvy oilfield service company.  With both companies committed to a strategy of integration, the Board sees this as a tremendous step forward” stated Mr. Tesarski.  He added, “It is time to ensure that our shareholders are rewarded for their loyalty to the company.”

As promised, as of August 27, 2014, the company has officially engaged auditors to begin to undertake the process of bringing the company into regulatory compliance.

“I am relieved that we have been able to now fully engage in the process of getting our company into compliance,” said Mr. Tesarski.  “It has been my number one priority.  I have promised this to shareholders and they deserve nothing less than a 100% commitment to compliance.”

In addition, the Board wishes to assure shareholders that the company will commit to providing them updates on or around the 15^th and 30^th days of the next few months following this announcement utilizing its social media resources while it transitions the company through this reorganization and growth phase.  The Board looks forward to continuing to provide its shareholders with positive developments in this new chapter in TREATY’s history.

Contact
Treaty Energy Corporation
Investor Relations
investors@treatyenergy.com
Tel: 504-301-4475

Company Links
Website: http://www.treatyenergy.com
Facebook: https://www.facebook.com/TreatyEnergyCorp
Twitter: https://twitter.com/TreatyEnergyCo

About Treaty Energy Corporation

Treaty, an international energy company, is engaged in the acquisition, development and production of oil and natural gas.  Treaty acquires and develops oil and gas leases which have “proven but undeveloped reserves” at the time of acquisition.  These properties are not strategic to large exploration-oriented oil and gas companies.  This strategy allows Treaty to develop and produce oil and natural gas with tremendously decreased risk, cost and time involved in traditional exploration.

About Sandbox Resource Solutions LLC

Sandbox Resource Solutions is a privately owned company dedicated to meeting your produced water requirements.  Our Resource Management System, “RMS” is engineered to remove oil, solids, iron sulphides and hydrocarbons and is proven to be more efficient and cost effective than traditional methods.  SRS is applying a patented proprietary technology to treat produced oilfield wastewater into useable, fresh water.  Our ground breaking technology is a 2 part system designed to reduce and reuse our most precious resource, water.  Micro-Encapsulating Flocculent Dispersion (“MFD”) and desalination allow us to optimise and maximize our natural resources.  The company’s focus is to deliver produced fresh water and subsequent by-products from its processes, which will be suitable for commercial, industrial and agriculture sustainability while reducing the strain on our natural resources.

http://www.sandboxresourcesolutions.com/

Treaty Energy Corporation (TECO) trades on the OTC.  Investors can find Real-Time quotes and market information for Treaty Energy at http://www.otcmarkets.com/stock/TECO/quote

Forward-Looking Statements

Statements herein express management’s beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, raising working capital and securing other financing; responding to competition and rapidly changing technology; and other risks.  These risks are detailed in the Company’s filings with the Securities and Exchange Commission, including Forms 10-KSB, 10-QSB and 8-K.  Actual results may differ materially from such forward-looking statements.

(IVAN) Responds to Trading Activity

CALGARY, Aug. 29, 2014  – Ivanhoe Energy Inc. (TSX: IE; NASDAQ: IVAN) said today that the company is not aware of any specific factors, other than information previously disclosed in its public filings, news releases or statements, which would result in the levels of trading activity and change in the share price recorded today.

In its most recent announcement August 27, Ivanhoe Energy confirmed its intention to fully participate in a new services contract presently under discussion for the development of the Block 20 oilfield development project in Ecuador (www.ivanhoeenergy.com/en/news/block_20_clarification_aug_2714_final.pdf).

This news release is being issued at the request of Market Surveillance at IIROC on behalf of the Toronto Stock Exchange.

Ivanhoe Energy is an independent international heavy oil exploration and development company focused on pursuing long-term growth in its reserves and production using advanced technologies, including its proprietary heavy oil upgrading process (HTL^®). Core operations are in Canada, United States, and Ecuador, with business development opportunities worldwide. Ivanhoe Energy trades on the Toronto Stock Exchange with the ticker symbol IE and on the NASDAQ Capital Market with the ticker symbol IVAN. For more information about Ivanhoe Energy Inc. please visit www.ivanhoeenergy.com.

FORWARD-LOOKING STATEMENTS: This document includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to the potential for commercialization and future application of the heavy oil upgrading technology and other technologies, statements relating to the continued advancement of Ivanhoe Energy’s projects, statements relating to the timing and amount of proceeds of agreed upon and contemplated disposition transactions, statements relating to anticipated capital expenditures, statements relating to the timing and success of regulatory review applications, and other statements which are not historical facts. When used in this document, the words such as “could,” “plan,” “estimate,” “expect,” “intend,” “may,” “potential,” “should,” and similar expressions relating to matters that are not historical facts are forward-looking statements. Although Ivanhoe Energy believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements include the potential that the Company’s projects will experience technological and mechanical problems, new product development will not proceed as planned, the HTL® technology to upgrade bitumen and heavy oil may not be commercially viable, geological conditions in reservoirs may not result in commercial levels of oil and gas production, the availability of drilling rigs and other support services, uncertainties about the estimates of reserves, the risk associated with doing business in foreign countries, environmental risks, changes in product prices, our ability to raise capital as and when required, our ability to complete agreed upon and planned asset dispositions, competition and other risks disclosed in Ivanhoe Energy’s 2013 Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on EDGAR and the Canadian Securities Commissions on SEDAR.